Analysis shows reduced survival linked to IDH2 and TP53 mutations in chondrosarcoma, suggesting a need for targeted clinical decisions.
IDH2 and TP53 mutations are enriched in dedifferentiated CS and are significant, independent predictors of adverse survival, regardless of tumor grade. These findings support IDH2 mutation status as clinically meaningful prognostic biomarker that may allow risk stratification and clinical decision-making in CS patients.
No takes yet. Share an insight, caveat, or question.
Weidlich et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: